50424-28-7

Basic information

• Product Name: 6-METHOXY-QUINAZOLIN-4-YLAMINE
• Synonyms: 6-METHOXY-QUINAZOLIN-4-YLAMINE;4-chloro-6-Methoxy-4a,8a-dihydroquinazoline;4-Chloro-6-Methoxyquinazo...
• CAS NO: 50424-28-7
• Molecular Formula: C₉H₇ClN₂O
• Molecular Weight: 175.19
• Mol File: 50424-28-7.mol
• Article Data: 15

Chemical Properties

• Melting Point: 107.5-108 °C
• Boiling Point: 322.973 °C at 760 mmHg
• Flash Point: 149.129 °C
• Appearance: /
• Density: 1.333 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.675
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.59±0.30(Predicted)
• CAS DataBase Reference: 6-METHOXY-QUINAZOLIN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-QUINAZOLIN-4-YLAMINE(50424-28-7)
• EPA Substance Registry System: 6-METHOXY-QUINAZOLIN-4-YLAMINE(50424-28-7)

Safety Data

• Hazardous Substances Data: 50424-28-7(Hazardous Substances Data)

Usage

General Description

6-Methoxy-quinazolin-4-ylamine is a chemical compound with the molecular formula C9H9N3O and a molecular weight of 175.19 g/mol. It is an aromatic amine derivative and contains a quinazoline ring with a methoxy substituent at the 6-position. 6-METHOXY-QUINAZOLIN-4-YLAMINE is of interest in medicinal chemistry and drug development due to its potential biological activities. It may have applications in pharmaceutical research as a precursor or building block for the synthesis of various biologically active compounds. Additionally, its specific interactions and mechanisms of action within biological systems could be the subject of further investigation. Overall, 6-Methoxy-quinazolin-4-ylamine has potential pharmacological and therapeutic relevance and may play a role in the development of novel drug compounds.

InChI:InChI=1/C9H9N3O/c1-13-6-2-3-8-7(4-6)9(10)12-5-11-8/h2-5H,1H3,(H2,10,11,12)

Upstream product

• 19181-64-7 6-methoxyquinazolin-4-ol 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 179246-11-8 4-chloroquinazoline-6-yl acetate 
• 16064-10-1 6-hydroxyquinazolin-4(3H)-one 
• 179688-15-4 3,4-dihydro-4-oxoquinazolin-6-yl acetate 
• 848438-50-6 4-chloroquinazolin-6-ol 
• 74-88-4 methyl iodide 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 1882-72-0 methyl 2-amino-5-hydroxybenzoate 
• 2475-80-1 methyl 2-amino-5-methoxybenzoate 
• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 77287-34-4 formamide 
• 19181-64-7 6-Methoxyquinazolin-4-one 

Downstream Products

• 2327-45-9 methyl 2-nitro-5-(methoxy)benzoate 
• 683269-72-9 4-(6-methoxy-quinazolin-4-yloxymethyl)-cyclohexanol 
• 1301760-33-7 4-(dimethylamino)-N-methyl-3-{[6-(methyloxy)-4-quinazolinyl]amino}benzenesulfonamide trifluoroacetate 
• 1613479-55-2 C₁₅H₁₀F₂N₂O₂ 
• 169205-79-2 N-(3-bromophenyl)-6-methoxyquinazolin-4-amine 

Relevant articles and documents

Quinazoline and phthalazine derivatives as novel melatonin receptor ligands analogues of agomelatine

For further development of successors of Agomelatine through modulation of its pharmacokinetic properties, we report herein the design, synthesis and pharmacological results of a new family of melatonin receptor ligands. Issued from the introduction of quinazoline and phthalazine scaffolds carrying an ethyl amide lateral chain and a methoxy group as bioisosteric ligands analogues of previously developed Agomelatine. The biological activity of the prepared analogues was compared with that of Agomelatine. Quinazoline and phthalazine rings proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands. Potent agonists with sub-micromolar binding affinity were obtained. However, the presence of two nitrogen atoms resulted in compounds with lower affinity for both MT1 and MT2, in comparison with the parent compound, balanced by the exhibition of good pharmacokinetic properties.

IDENTIFICATION AND USE OF ERK5 INHIBITORS

The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.

Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1

The ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) was recently shown to promote mineralization of the aortic valve, hence, its inhibition represents a significant target. A quinazoline-4-piperidine sulfamide compound (QPS1) has been described as a specific and non-competitive inhibitor of NPP1. We report herein the synthesis and in vitro inhibition studies of novel quinazoline-4-piperidine sulfamide analogues using QPS1 as the lead compound. Of the 26 derivatives prepared, four compounds were found to have Ki 105 nM against human NPP1.